Determination of GTI-2040, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquid–liquid extractions
- 27 December 2005
- journal article
- research article
- Published by Elsevier in Journal of Chromatography B
- Vol. 829 (1-2) , 45-49
- https://doi.org/10.1016/j.jchromb.2005.09.036
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Quantification of raf antisense oligonucleotide (rafAON) in biological matrices by LC-MS/MS to support pharmacokinetics of a liposome-entrapped rafAON formulationBiomedical Chromatography, 2004
- Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphomaAnnals of Oncology, 2004
- A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumorsAnnals of Oncology, 2004
- Structure, function, and mechanism of ribonucleotide reductasesBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2004
- A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weeklyAnnals of Oncology, 2003
- Quantitation of Phosphorothioate Oligonucleotides in Human PlasmaAnalytical Biochemistry, 1996
- Quantitative analysis of phosphorothioate oligonucleotides in biological fluids using direct injection fast anion-exchange chromatography and capillary gel electrophoresisJournal of Chromatography B: Biomedical Sciences and Applications, 1994
- Quantitative analysis of phosphorothioate oligonucleotides in biological fluids using fast anion-exchange chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1993